Synthetic Biologics paws Kraws for chair
This article was originally published in Scrip
Synthetic Biologics, a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, has split the roles of chair and CEO and appointed Jeffrey Kraws chair, while Jeffrey Riley remains CEO, president and director. Mr Kraws, who is CEO and co-founder of Crystal Research Associates, has been a member of Synthetic Biologics' board since 2006.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.